All IndicationsInfectious DiseasePhase 3Phase 3Phase 2Phase 2
🦠
Influenza
3
Companies
4
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
SNY
Sanofi
A/H1N1 pandemic influenza vaccine (non- adjuvanted)
BNTX
BioNTech SE
Influenza and COVID-19 Combination A
BNTX
BioNTech SE
Investigational COVID-19 Vaccine
NVS
Novartis AG
Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| SNY Sanofi | A/H1N1 pandemic influenza vaccine (non- adjuvanted) | Phase 3 | — | — | — |
| BNTX BioNTech SE | Influenza and COVID-19 Combination A | Phase 3 | — | — | — |
| BNTX BioNTech SE | Investigational COVID-19 Vaccine | Phase 2 | — | — | — |
| NVS Novartis AG | Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008 | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
2
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.